The U.S. launch of a biosimilar to AbbVie’s Humira appears to be hurting the copycat’s developer itself. After AbbVie reported a Humira U.S. sales decline of 26% in the first quarter, Amgen said its ...

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that competition for early-line use of Amgen/Pfizer's Enbrel and ...

Shares of the immunology juggernaut AbbVie (NYSE: ABBV) were down by 4% on sky-high volume as of 11 a.m. ET Thursday. That's equivalent to a $7 billion drop in market capitalization. What's spooking ...

LONDON, March 15 (Reuters) - Abbott Laboratories' drug Humira and Enbrel, from Pfizer and Amgen , should be the first choices for treating patients with psoriatic arthritis, Britain's ...

The Supreme Court declined to review a petition filed by Novartis’ Sandoz unit that challenged two of Amgen’s patents on its blockbuster rheumatoid arthritis drug, Enbrel, meaning there won’t be a ...

A major California health plan has struck a novel deal directly with a drug manufacturer for a cheaper version of Humira, cutting out pharmacy benefit managers — controversial middlemen in the drug ...